about
The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice.The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cellsAltered donor P2X7 activity in human leukocytes correlates with P2RX7 genotype but does not affect the development of graft-versus-host disease in humanised miceThe P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A miceLong-term treatment with the P2X7 receptor antagonist Brilliant Blue G reduces liver inflammation in a humanized mouse model of graft-versus-host diseaseIncreased splenic human CD4+:CD8+ T cell ratios, serum human interferon-γ and intestinal human interleukin-17 are associated with clinical graft-versus-host disease in humanized miceThe A2A receptor agonist CGS 21680 has beneficial and adverse effects on disease development in a humanised mouse model of graft-versus-host diseasePharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease
P50
Q47144272-2F7E314C-7E54-4971-8D2B-DCF8D38BD783Q48194542-C64C4224-31E2-40FC-A8A3-463D47C4BF9EQ87655511-15F77D0D-9A04-4766-A9C8-2D6485580087Q90005205-EA066192-E644-468F-98BD-C5D0871BFB01Q90319920-6392F924-4B2C-414F-91C5-6473208B2EDFQ90460297-7CB98F69-B84B-4178-9446-18D0B5CF4832Q91455807-985D8620-7CCE-483E-8C39-5E0BE917D560Q91734967-B930B2D1-0754-4402-8CBD-E89AB6702D92Q92917365-2DDF3FF2-B388-4E2F-9461-0101548A5E91
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Nicholas J Geraghty
@en
Nicholas J Geraghty
@nl
type
label
Nicholas J Geraghty
@en
Nicholas J Geraghty
@nl
prefLabel
Nicholas J Geraghty
@en
Nicholas J Geraghty
@nl
P31
P496
0000-0001-9098-8224